Trending Now
Sorrento Therapeutics Inc (NASDAQ: SRNE) Announced its FDA Approval to begin...
Sorrento Therapeutics Inc (NASDAQ: SRNE) recently announced that it got approval from the FDA to conduct a Phase I clinical trial of its anti-CD38 DAR...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Synaptogenix Inc (NASDAQ: SNPX) Announces a Peer-reviewed Paper on Bryostatin
Synaptogenix Inc (NASDAQ: SNPX) announced a peer-reviewed paper published in the Frontiers Aging Neuroscience. The paper came from a collaboration between the company’s Chief...
MAKE IT MODERN
LATEST REVIEWS
Synthetic Biologics Inc. (NYSEAMERICAN: SYN) commences Recruitment and Doses Eight Patients...
Synthetic Biologics Inc. (NYSEAMERICAN: SYN) has commenced enrolment and dosing of eight trial participants in the Phase 1 multiple-ascending dose (MAD), placebo-controlled clinical study...
MAKE IT MODERN
PERFORMANCE TRAINING
Artelo Biosciences Inc (NASDAQ:ARTL) Posts Net Loss Of $951,395 In Q3 2020
Artelo Biosciences Inc (NASDAQ:ARTL) widened net loss by 175.80% to $951,395 in Q3 2020. Its operating expenses related to R&D, administrative and general expenses...
Inovio Pharmaceuticals Inc. (NASDAQ:INO) Responds To FDA Questions On Halted Phase II/III INO-4800 Study
Inovio Pharmaceuticals Inc. (NASDAQ:INO) has responded to questions from the FDA regarding INO-4800 and the Cellectra vaccine delivery device. The FDA had imposed a...
Pfizer’s (NYSE: PFE) Ponsegromab Shows Promise in Fighting Cancer Cachexia
Pfizer (NYSE: PFE) recently announced positive results from a midstage trial of their experimental drug, ponsegromab, designed to treat cancer cachexia, a...
NovoCure Limited (NASDAQ: NVCR): Groundbreaking PANOVA-3 Trial Results Signal Hope for Pancreatic Cancer Patients
NovoCure Limited (NASDAQ: NVCR) achieved a major milestone with the announcement of positive results from its pivotal Phase 3 PANOVA-3 trial, conducted...
CymaBay Therapeutics Inc. (NASDAQ:CBAY) Announce Its Q3 2020 Results And Progress Of Seladelpar Development...
CymaBay Therapeutics Inc. (NASDAQ:CBAY) has announced its financial results for Q3 2020 and nine months ended September 30, 2020, and provided corporate updates.
CymaBay’s ENHANCE...
MAKE IT MODERN
